Business Context and Reporting Period
This Form 8-K is a current report filed by XpresSpa Group, Inc. (trading symbol: XSPA) on January 31, 2022. The registrant is incorporated in Delaware and operates as an emerging growth company. The filing primarily addresses a material contract extension under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the reporting period. The only specific financial figure disclosed relates to a government contract:
- Contract Value: The Company extended its airport-based biosurveillance program with the Centers for Disease Control and Prevention (CDC) through its subsidiary, XpresCheck.
- Extension Amount: $2 million.
- Total Contract Value: $5.6 million.
Material Changes
The primary material change reported is the expansion of the Company's biosurveillance operations. The initial $2 million program with the CDC has been extended, increasing the total contract value to $5.6 million. No other material changes to financial position or operations are detailed in this specific filing.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) regarding the CDC contract extension. The document explicitly states that the information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. Consequently, no formal forward-looking guidance, risk factors, or management commentary beyond the contract announcement is provided within the text of this 8-K.
Investor Verification Checklist
- Verify the terms and duration of the extended CDC biosurveillance contract in the attached press release (Exhibit 99.1).
- Confirm the revenue recognition timeline for the additional $2 million contract extension.
- Review the Company's most recent 10-K or 10-Q for comprehensive financial data, as this 8-K does not contain full financial statements.
- Assess the strategic importance of the XpresCheck subsidiary to the Company's overall revenue mix.